| Name | Olsalazine disodium |
| Description | Olsalazine disodium (Dipentum) is bioconverted to 5-aminosalicylic acid (5-ASA) in the colon and has anti-inflammatory activity in ulcerative colitis. |
| In vitro | In nu/nu CD-1 mice with experimental colitis induced by sodium dextran sulfate, daily treatment with Olsalazine (50 mg/kg) led to the bacterial azoreductase cleavage of azo bonds, releasing mesalazine, which is capable of treating colitis. |
| In vivo | In isolated rat ileal and guinea pig ileal mucosa, Olsalazine (less than 2.89 mM) increases the secretion of sodium and chloride ions, while decreasing the absorption of chloride ions. In isolated rat colonic tissues, Olsalazine (less than 11.5 mM) reduces net sodium levels and chloride ion absorption in a dose-dependent manner, and at high concentrations (11.5 mM), it increases potassium secretion. Moreover, in isolated rat jejunum, Olsalazine inhibits the absorption of glucose and lactose. In human intestinal macrophages (IC50=0.39 mM), Olsalazine acts as an effective inhibitor of the chemotaxis of LTB4. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 38 mg/mL (109.8 mM)
DMSO : 50 mg/mL (144.43 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Olsalazine disodium | Antibiotic | Olsalazine | Bacterial | inhibit | Inhibitor |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Kanamycin sulfate | Sulfamethoxazole sodium | Metronidazole | Doxycycline | EDTA copper(II) disodium salt | Dimethyl sulfoxide | Salicylic acid | Crystal Violet |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
